Literature DB >> 27466417

Multiple Transcripts Encode Full-Length Human Cytomegalovirus IE1 and IE2 Proteins during Lytic Infection.

Kyle C Arend1, Benjamin Ziehr1, Heather A Vincent1, Nathaniel J Moorman2.   

Abstract

UNLABELLED: Expression of the human cytomegalovirus (HCMV) IE1 and IE2 proteins is critical for the establishment of lytic infection and reactivation from viral latency. Defining the mechanisms controlling IE1 and IE2 expression is therefore important for understanding how HCMV regulates its replicative cycle. Here we identify several novel transcripts encoding full-length IE1 and IE2 proteins during HCMV lytic replication. Two of the alternative major immediate early (MIE) transcripts initiate in the first intron, intron A, of the previously defined MIE transcript, while others extend the 5' untranslated region. Each of the MIE transcripts associates with polyribosomes in infected cells and therefore contributes to IE1 and IE2 protein levels. Surprisingly, deletion of the core promoter region of the major immediate early promoter (MIEP) from a plasmid containing the MIE genomic locus did not completely abrogate IE1 and IE2 expression. Instead, deletion of the MIEP core promoter resulted in increased expression of alternative MIE transcripts, suggesting that the MIEP suppresses the activity of the alternative MIE promoters. While the canonical MIE mRNA was the most abundant transcript at immediate early times, the novel MIE transcripts accumulated to levels equivalent to that of the known MIE transcript later in infection. Using two HCMV recombinants, we found that sequences in intron A of the previously defined MIE transcript are required for efficient IE1 and IE2 expression and viral replication. Together, our results identify new regulatory sequences controlling IE1 and IE2 expression and suggest that multiple transcription units act in concert to regulate IE1 and IE2 expression during lytic infection. IMPORTANCE: The HCMV IE1 and IE2 proteins are critical regulators of HCMV replication, both during primary infection and reactivation from viral latency. This study expands our understanding of the sequences controlling IE1 and IE2 expression by defining novel transcriptional units controlling the expression of full-length IE1 and IE2 proteins. Our results suggest that alternative promoters may allow for IE1 and IE2 expression when MIEP activity is limiting, as occurs in latently infected cells.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27466417      PMCID: PMC5021424          DOI: 10.1128/JVI.00741-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  Viable human cytomegalovirus recombinant virus with an internal deletion of the IE2 86 gene affects late stages of viral replication.

Authors:  Veronica Sanchez; Charles L Clark; Judy Y Yen; Roopashree Dwarakanath; Deborah H Spector
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Functional map of human cytomegalovirus AD169 defined by global mutational analysis.

Authors:  Dong Yu; Maria C Silva; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

3.  Interaction between the human cytomegalovirus UL82 gene product (pp71) and hDaxx regulates immediate-early gene expression and viral replication.

Authors:  Stacy R Cantrell; Wade A Bresnahan
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

4.  Regulated expression of early and late RNAs and proteins from the human cytomegalovirus immediate-early gene region.

Authors:  R M Stenberg; A S Depto; J Fortney; J A Nelson
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

5.  Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication.

Authors:  Nathaniel J Moorman; Thomas Shenk
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

6.  Analysis of splice variants of the immediate-early 1 region of human cytomegalovirus.

Authors:  Sita Awasthi; Jennifer A Isler; James C Alwine
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

7.  Influence of promoter potency on the transcriptional effects of YY1, SRF and Msx-1 in transient transfection analysis.

Authors:  T Lee; M E Bradley; J L Walowitz
Journal:  Nucleic Acids Res       Date:  1998-07-01       Impact factor: 16.971

8.  Tale of a tegument transactivator: the past, present and future of human CMV pp71.

Authors:  Rhiannon R Penkert; Robert F Kalejta
Journal:  Future Virol       Date:  2012-09-01       Impact factor: 1.831

9.  Murine gammaherpesvirus 68 has evolved gamma interferon and stat1-repressible promoters for the lytic switch gene 50.

Authors:  Megan M Goodwin; Susan Canny; Ashley Steed; Herbert W Virgin
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

10.  Human cytomegalovirus immediate-early 2 (IE2) protein can transactivate the human hsp70 promoter by alleviation of Dr1-mediated repression.

Authors:  R Caswell; L Bryant; J Sinclair
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more
  19 in total

1.  The essential role of guinea pig cytomegalovirus (GPCMV) IE1 and IE2 homologs in viral replication and IE1-mediated ND10 targeting.

Authors:  Julia Hornig; K Yeon Choi; Alistair McGregor
Journal:  Virology       Date:  2017-02-10       Impact factor: 3.616

2.  Alternative promoters drive human cytomegalovirus reactivation from latency.

Authors:  Donna Collins-McMillen; Mike Rak; Jason C Buehler; Suzu Igarashi-Hayes; Jeremy P Kamil; Nathaniel J Moorman; Felicia Goodrum
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-13       Impact factor: 11.205

3.  Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) Antivirals.

Authors:  Kyle C Arend; Erik M Lenarcic; Heather A Vincent; Naim Rashid; Eric Lazear; Ian M McDonald; Thomas S K Gilbert; Michael P East; Laura E Herring; Gary L Johnson; Lee M Graves; Nathaniel J Moorman
Journal:  Mol Cell Proteomics       Date:  2017-02-25       Impact factor: 5.911

4.  FOXO transcription factors activate alternative major immediate early promoters to induce human cytomegalovirus reactivation.

Authors:  Andrew E Hale; Donna Collins-McMillen; Erik M Lenarcic; Suzu Igarashi; Jeremy P Kamil; Felicia Goodrum; Nathaniel J Moorman
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-21       Impact factor: 11.205

5.  miRNA-mediated targeting of human cytomegalovirus reveals biological host and viral targets of IE2.

Authors:  Rasmus Møller; Toni M Schwarz; Vanessa M Noriega; Maryline Panis; David Sachs; Domenico Tortorella; Benjamin R tenOever
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-16       Impact factor: 11.205

6.  The 5' Untranslated Region of the Major Immediate Early mRNA Is Necessary for Efficient Human Cytomegalovirus Replication.

Authors:  Kyle C Arend; Erik M Lenarcic; Nathaniel J Moorman
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

7.  Activator protein-1 transactivation of the major immediate early locus is a determinant of cytomegalovirus reactivation from latency.

Authors:  Benjamin A Krishna; Amanda B Wass; Christine M O'Connor
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-11       Impact factor: 11.205

8.  CMV-encoded GPCR pUL33 activates CREB and facilitates its recruitment to the MIE locus for efficient viral reactivation.

Authors:  Benjamin A Krishna; Amanda B Wass; Abigail L Dooley; Christine M O'Connor
Journal:  J Cell Sci       Date:  2021-01-25       Impact factor: 5.285

9.  Editorial: Cytomegalovirus Pathogenesis and Host Interactions.

Authors:  Emma L Poole; Michael M Nevels
Journal:  Front Cell Infect Microbiol       Date:  2021-07-07       Impact factor: 5.293

10.  Long-Read Sequencing of Human Cytomegalovirus Transcriptome Reveals RNA Isoforms Carrying Distinct Coding Potentials.

Authors:  Zsolt Balázs; Dóra Tombácz; Attila Szűcs; Zsolt Csabai; Klára Megyeri; Alexey N Petrov; Michael Snyder; Zsolt Boldogkői
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.